CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 19:04:58 31/05/2024 BST | ||
| 7.65 EUR | +16.26% |
|
| 1 month | +187.59% | ||
| 3 months | +28.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 7.65 | +16.26% |
| 30/05/24 | 6.58 | -4.91% |
| 29/05/24 | 6.92 | -4.95% |
| 28/05/24 | 7.28 | -14.65% |
| 27/05/24 | 8.53 | +3.90% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 07:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM6W8W |
| ISIN | DE000VM6W8W0 |
| Date issued | 12/12/2023 |
| Strike | 370.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.53 € |
|---|---|
| Lowest since issue | 0.36 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
